|
|
|
|
|
|
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase IIa, Randomized, Double-blind, Placebo-controlled, Exploratory, Dose-ranging Study to Evaluate the Safety, Effectiveness and Pharmacokinetics of Three Courses of DC-TAB Treatment in Patients With Multiple Sclerosis
The purpose of this study is to evaluate safety and clinical efficacy of DC-TAB in multiple sclerosis.
/ CompletedNot Applicable *A Phase I, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics and T-cell tolerizing effect of DC-TAB in healthy volunteers, after single and multiple dosing* - A phase I trial with DC-TAB
A Phase I, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and T-cell Tolerizing Effect of DC-TAB in Healthy Volunteers
The purpose of this study is to determine safety and appropriate dose of DC-TAB for selective immune tolerance induction in humans.
100 Clinical Results associated with Delta Crystallon BV
0 Patents (Medical) associated with Delta Crystallon BV
100 Deals associated with Delta Crystallon BV
100 Translational Medicine associated with Delta Crystallon BV